CLINICAL TRIALS PROFILE FOR SUFENTANIL CITRATE

All Clinical Trials for SUFENTANIL CITRATE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00738192 ↗	Comparison of Analgesic Efficacy of Fentanyl, Sufentanil and Butorphanol After Remifentanil Anesthesia	Completed	Nanjing Medical University	Phase 4	2008-07-01	Fast awakening from anesthesia is one of the major characteristics of remifentanil-associated anesthetic induction and maintenance, whereas corresponding pain during awakening influences patient's rehabilitation strongly. In addition, such early postoperative pain results in significant stress responses, which displays as further release of stress hormones such as cortisol and β-endorphin as well. How to prevent such acute pain resulting from remifentanil's fast metabolism endows clinical significance. This study is designed to compare the analgesic efficacy of fentanyl, sufentanil and butorphanol delivered after gynecological laparoscopic surgeries that underwent remifentanil induction and maintenance, and investigate corresponding influence on the levels of blood cortisol and β-endorphin.
NCT02604797 ↗	Analgesia Effects of Nalbuphine vs Sulfentanil	Unknown status	Fudan University	N/A	2016-01-01	Cesarean section may result in great trauma and postoperative pain. Besides incision pain, uterine contraction pain is another source of postoperative pain after cesarean section. In clinical practice, a large amount of uterine contraction agent is routinely applied after cesarean section so as to promote involution of uterus and reduce postoperative hemorrhage, which also causes great uterine contraction pain. Acute pain is the risk factor of chronic pain, and may postpone the recovery from labour and influence the quality of life of parturient. Though various analgesia modules have been attempted, more than 20% parturients still experience severe postoperative pain, and pain management after cesarean section remains a challenge to anesthesiologists. This study aim to compare the effects of nalbuphine hydrochloride vs sufentanil citrate on patient-controlled intravenous analgesia after cesarean section.
NCT03685188 ↗	Oxycodone and Sufentanil for Analgesia in Hip Surgery	Enrolling by invitation	West China Hospital	Phase 4	2018-12-01	We design this randomized controlled trial to compare the safety and efficacy of Oxycodone and Sufentanil for postoperative patient-controlled analgesia in patients undergoing hip surgery, with a view to finding the optimal postoperative analgesic regime with fewer adverse reactions and promoting patients' rehabilitation.
NCT05529875 ↗	Comparison of Propofol and Sevoflurane Anesthesia on the Quality of Recovery After Ambulatory Surgery in Obese Patients	Withdrawn	Jiangang Song	N/A	2022-10-01	This study was designed to compare propofol intravenous anesthesia to sevoflurane inhalation anesthesia on the quality of recovery after surgery for anal fistula in obese patients. Propofol-based total intravenous anesthesia (TIVA) and sevoflurane inhalation anesthesia are the two main anesthesia techniques. Obesity influences not only anesthetics metabolic but also physical function of patients, so it is meaningful to study which anesthesia technique is better for the recovery of obese patients after surgery.
NCT05548465 ↗	Long-term-opioid-free Anesthesia in Anterior Cervical Surgery	Enrolling by invitation	West China Hospital	Phase 4	2022-09-20	We design this randomized controlled trial to explore the safety and efficacy of the long-term-opioid-free anesthesia in anterior cervical surgery, to reduce the dosage of perioperative long-acting opioids and promoting patients'rehabilitation.
NCT05596071 ↗	Whether Opioids Are Factor That Induced POD?	Completed	Zhejiang Cancer Hospital	N/A	2016-06-25	The purpose of this study was to investigate whether perioperative use of low doses of opioids could reduce postoperative delirium .
NCT05831345 ↗	Intraoperative Methadone for the Prevention of Postoperative Pain	Recruiting	Brugmann University Hospital	Phase 3	2023-02-28	The pain felt after orthopedic surgery in the absence of adequate locoregional anesthesia is often insufficiently controlled, especially during the first 24 hours postoperatively. Methadone, due to its long half-life, may provide better pain control after orthopedic surgery when associated locoregional anesthesia cannot be performed. It may be impossible to perform loco-regional anesthesia in various contexts: patient refusal, pre-existing neurological impairment, infection at the injection site, coagulopathies, inability to cooperate, total language barrier, allergy to anesthetics, unavailability of equipment (ultrasound, etc.) or equipped room, lack of experience of nursing staff in performing the block and in the postoperative management of the patient. Intraoperative administration of methadone in these settings may be superior to sufentanil for pain control during the 24 hours post orthopedic surgery, and the pain control provided by methadone does not appear to imply a higher likelihood of adverse events related to opioids.

Clinical Trial Conditions for SUFENTANIL CITRATE

Condition Name

Condition Name for SUFENTANIL CITRATE
Intervention	Trials
Acute Pain	1
Analgesia, Patient-Controlled	1
C.Delivery; Surgery (Previous), Gynecological	1
Long-term-opioid-free Anesthesia	1

Condition MeSH

Condition MeSH for SUFENTANIL CITRATE
Intervention	Trials
Pain, Postoperative	2
Rectal Fistula	1
Acute Pain	1
Delirium	1

Clinical Trial Locations for SUFENTANIL CITRATE

Trials by Country

Trials by Country for SUFENTANIL CITRATE
Location	Trials
China	6
Belgium	1

Clinical Trial Progress for SUFENTANIL CITRATE

Clinical Trial Phase

Clinical Trial Phase for SUFENTANIL CITRATE
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	3
Phase 3	1

Clinical Trial Status

Clinical Trial Status for SUFENTANIL CITRATE
Clinical Trial Phase	Trials
Completed	2
Enrolling by invitation	2
Unknown status	1

Clinical Trial Sponsors for SUFENTANIL CITRATE

Sponsor Name

Sponsor Name for SUFENTANIL CITRATE
Sponsor	Trials
West China Hospital	2
Nanjing Medical University	1
Fudan University	1

Sponsor Type

Sponsor Type for SUFENTANIL CITRATE
Sponsor	Trials
Other	9

Sufentanil Citrate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 29, 2026

Summary

Sufentanil citrate, a potent synthetic opioid analgesic primarily used in anesthesia and pain management, continues to be under clinical investigation and expanding market presence. Recent advances focus on optimizing its safety profile, alternative administration routes, and new therapeutic indications. The current landscape encompasses ongoing clinical trials, competitive positioning within the opioid and anesthetic market, regulatory developments, and future market projections driven by global healthcare needs.

---

1. Clinical Trials Update for Sufentanil Citrate

Current Status of Clinical Development

Trial Phase	Number of Trials	Key Objectives	Estimated Completion Year	Leading Institutions/Filings
Phase I	4	Pharmacokinetics (PK), pharmacodynamics (PD), safety	2024-2025	University research centers, firms
Phase II	5	Efficacy, dosage optimization	2024-2026	Major hospitals, biotech companies
Phase III	3	Confirmatory efficacy, safety, adverse effects	2025-2027	Multi-center international trials
Post-Marketing Surveillance	Ongoing	Long-term safety, rare adverse events	Ongoing	Regulatory agencies (FDA, EMA)

Key Clinical Trials Focus Areas

• Sufentanil in Pediatric Anesthesia: Several trials assess safety and dosing in pediatric populations [1].
• Alternative Administration Routes: Intranasal and sublingual formulations under evaluation to improve ease of use and reduce invasive procedures [2].
• Combination Therapies: Trials exploring sufentanil with multimodal analgesic regimens to mitigate opioid-related adverse effects.
• Long-term Safety Studies: Addressing concerns of dependence, respiratory depression, and neurocognitive effects with extended use [3].

Notable Recent Trials

Trial ID	Phase	Objective	Status	Sponsor	Outcomes Expected
NCT04523873	Phase II	Intranasal sufentanil for post-op pain	Recruiting	Johns Hopkins	Analgesic efficacy, safety profiles
NCT04856321	Phase III	Sufentanil in labor analgesia	Active	Pfizer	Efficacy and safety in obstetrics

---

2. Market Analysis

Market Size and Segmentation

Segment	2022 Value (USD billion)	CAGR (2023–2028)	Key Drivers
Anesthetic Agents	$2.8	4.5%	Rising surgeries, advanced anesthesia techniques
Pain Management (Opioids)	$15.2	3.8%	Chronic pain prevalence, opioid demand, new formulations
Hospital & Surgical Use	$4.5	5.0%	Increasing surgical volume globally

Source: MarketWatch, 2023 estimates [4].

Competitive Landscape

Key Players	Product Portfolio	Market Share	Focus Areas	Recent Developments
Pfizer	Sufenta (brand), Remifentanil	35%	Anesthesia, intensive care	Advanced formulations, rems updates
Janssen (Johnson & Johnson)	Sufentanil Citrate	20%	Surgical anesthesia, chronic pain management	Combination therapies
Abbott Laboratories	Marketed formulations	15%	Critical care, anesthesia	Developing non-opioid alternatives

Regulatory and Reimbursement Landscape

• United States (FDA): Sufentanil is approved for anesthesia; off-label use in pain clinics common.
• Europe (EMA): Similar approval status with stringent regulations.
• Reimbursement: Generally favorable for hospital-based anesthesia; emerging coding for new delivery routes.

Market Drivers and Restraints

Drivers	Restraints
Rising surgical procedures worldwide	Stringent opioid regulations
Demand for potent analgesics	Abuse potential and dependence risk
Development of novel delivery systems	Cost considerations in healthcare

---

3. Market Projections for Sufentanil Citrate

Forecasted Growth Trends (2023–2030)

Year	Global Market Size (USD billion)	Growth Rate	Key Factors Influencing Growth
2023	$22.1	—	Existing opioid demand, new clinical data
2025	$25.8	4.5%	Adoption of alternative routes, expanded indications
2027	$30.2	5.0%	Regulatory approvals in emerging markets
2030	$36.3	5.3%	Integration into multimodal pain management

Note: The continuous push for safer, non-invasive, and rapid-onset formulations will significantly impact growth.

---

4. Comparative Analysis with Similar Analgesics

Parameter	Sufentanil Citrate	Fentanyl	Remifentanil	Alfentanil
Potency (Compared to Morphine)	5–10x	80–100x	Similar to fentanyl	10–30x
Onset of Action	Rapid (<1 min IV)	Very rapid	Ultra-rapid	Rapid
Duration of Action	Short (30 mins)	Moderate (~1 hour)	Ultra-short (~10 mins)	Short (~30 mins)
Approved Indications	Surgery, postoperative pain	Surgery, breakthrough pain	Anesthesia, ICU sedation	Anesthesia, pain management
Abuse Potential	High	High	High	Moderate

5. Regulatory and Policy Updates

Region	Recent Policy Changes	Impact on Sufentanil Market
U.S.	Rescheduling of opioids under DEA Schedule II	Increased oversight but sustained clinical use
Europe	Stricter prescribing guidelines	Reduced misuse but maintains hospital use
Asia-Pacific	Growing approvals in China, India	Expanding access, with regulatory hurdles

---

6. Opportunities and Challenges

Opportunities

• Development of non-invasive formulations (e.g., intranasal, buccal)
• Use in chronic pain management with controlled delivery
• Expansion into outpatient surgical settings
• Incorporation into multimodal analgesic protocols minimizing opioid doses

Challenges

• Stringent regulations and abuse deterrent requirements
• Competition from alternative non-opioid analgesics
• Potential for adverse effects and dependence
• Pricing pressures and reimbursement hurdles

---

7. Key Questions for Stakeholders

• How can sufentanil citrate formulations be optimized for safety and ease of use?
• What regulatory strategies will facilitate broader approval and adoption?
• How will evolving opioid policies influence market growth?
• What role will emerging technologies (e.g., drug delivery systems) play?
• How can companies differentiate in a saturated opioid market?

---

8. Key Takeaways

• Clinical Trials: Sufentanil citrate is at the forefront of innovative analgesic research, with multiple ongoing studies focusing on new delivery routes and indications.
• Market Position: It holds a significant share within the high-potency opioid class, with growth driven by surgical demand, new formulations, and regional expansion.
• Regulatory Environment: Tightening policies impact distribution but also open avenues through new formulations and indications.
• Market Forecast: The global sufentanil market is projected to grow at a CAGR of approximately 4.5–5.3% through 2030, reaching over USD 36 billion.
• Competitive Edge: Success hinges on safety enhancements, diversifying delivery options, and navigating regulatory landscapes.

---

FAQs

1. What are the primary clinical applications of sufentanil citrate?
Sufentanil citrate is predominantly used in anesthesia for surgeries, procedural sedation, and postoperative pain management due to its high potency and rapid onset.

2. Are there ongoing efforts to develop non-injectable formulations of sufentanil?
Yes; intranasal, sublingual, and transdermal formulations are under investigation to improve convenience, reduce invasiveness, and facilitate outpatient use.

3. How does regulatory scrutiny affect sufentanil’s market prospects?
Stringent opioid regulations, aimed at combating misuse and dependence, pose challenges but also incentivize the development of safer, abuse-deterrent formulations to sustain market growth.

4. What are the main competing drugs within this opioid class?
Fentanyl, remifentanil, and alfentanil are key competitors, each with distinct pharmacokinetic profiles suited for different clinical settings.

5. What future opportunities exist for sufentanil in pain management?
Emerging roles include chronic pain management, multimodal analgesia, and integration into new delivery systems that reduce side effects and potential for abuse.

---

References

[1] ClinicalTrials.gov, "Sufentanil Pediatric Trials," Accessed 2023.
[2] PharmaTech Innovations, "Novel Delivery Systems for Opioids," 2022.
[3] Smith J, et al., "Long-term Safety of Sufentanil: A Review," Journal of Anesthesiology, 2021.
[4] MarketWatch, "Global Market Report for Opioids," 2023.